New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication
Obesity and type 2 diabetes are recognised risk factors for the development of some cancers and, increasingly, predict more aggressive disease, treatment failure, and cancer-specific mortality. Many factors may contribute to this clinical observation. Hyperinsulinaemia, dyslipidaemia, hypoxia, ER st...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | International Journal of Cell Biology |
| Online Access: | http://dx.doi.org/10.1155/2013/834684 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559044891508736 |
|---|---|
| author | Jennifer H. Gunter Phoebe L. Sarkar Amy A. Lubik Colleen C. Nelson |
| author_facet | Jennifer H. Gunter Phoebe L. Sarkar Amy A. Lubik Colleen C. Nelson |
| author_sort | Jennifer H. Gunter |
| collection | DOAJ |
| description | Obesity and type 2 diabetes are recognised risk factors for the development of some cancers and, increasingly, predict more aggressive disease, treatment failure, and cancer-specific mortality. Many factors may contribute to this clinical observation. Hyperinsulinaemia, dyslipidaemia, hypoxia, ER stress, and inflammation associated with expanded adipose tissue are thought to be among the main culprits driving malignant growth and cancer advancement. This observation has led to the proposal of the potential utility of “old players” for the treatment of type 2 diabetes and metabolic syndrome as new cancer adjuvant therapeutics. Androgen-regulated pathways drive proliferation, differentiation, and survival of benign and malignant prostate tissue. Androgen deprivation therapy (ADT) exploits this dependence to systemically treat advanced prostate cancer resulting in anticancer response and improvement of cancer symptoms. However, the initial therapeutic response from ADT eventually progresses to castrate resistant prostate cancer (CRPC) which is currently incurable. ADT rapidly induces hyperinsulinaemia which is associated with more rapid treatment failure. We discuss current observations of cancer in the context of obesity, diabetes, and insulin-lowering medication. We provide an update on current treatments for advanced prostate cancer and discuss whether metabolic dysfunction, developed during ADT, provides a unique therapeutic window for rapid translation of insulin-sensitising medication as combination therapy with antiandrogen targeting agents for the management of advanced prostate cancer. |
| format | Article |
| id | doaj-art-fa7a19140bff4d8595aee7ee81b98c3c |
| institution | Kabale University |
| issn | 1687-8876 1687-8884 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Cell Biology |
| spelling | doaj-art-fa7a19140bff4d8595aee7ee81b98c3c2025-02-03T01:31:07ZengWileyInternational Journal of Cell Biology1687-88761687-88842013-01-01201310.1155/2013/834684834684New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising MedicationJennifer H. Gunter0Phoebe L. Sarkar1Amy A. Lubik2Colleen C. Nelson3Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, 199 Ipswich Road, Brisbane, QLD 4102, AustraliaAustralian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, 199 Ipswich Road, Brisbane, QLD 4102, AustraliaAustralian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, 199 Ipswich Road, Brisbane, QLD 4102, AustraliaAustralian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, 199 Ipswich Road, Brisbane, QLD 4102, AustraliaObesity and type 2 diabetes are recognised risk factors for the development of some cancers and, increasingly, predict more aggressive disease, treatment failure, and cancer-specific mortality. Many factors may contribute to this clinical observation. Hyperinsulinaemia, dyslipidaemia, hypoxia, ER stress, and inflammation associated with expanded adipose tissue are thought to be among the main culprits driving malignant growth and cancer advancement. This observation has led to the proposal of the potential utility of “old players” for the treatment of type 2 diabetes and metabolic syndrome as new cancer adjuvant therapeutics. Androgen-regulated pathways drive proliferation, differentiation, and survival of benign and malignant prostate tissue. Androgen deprivation therapy (ADT) exploits this dependence to systemically treat advanced prostate cancer resulting in anticancer response and improvement of cancer symptoms. However, the initial therapeutic response from ADT eventually progresses to castrate resistant prostate cancer (CRPC) which is currently incurable. ADT rapidly induces hyperinsulinaemia which is associated with more rapid treatment failure. We discuss current observations of cancer in the context of obesity, diabetes, and insulin-lowering medication. We provide an update on current treatments for advanced prostate cancer and discuss whether metabolic dysfunction, developed during ADT, provides a unique therapeutic window for rapid translation of insulin-sensitising medication as combination therapy with antiandrogen targeting agents for the management of advanced prostate cancer.http://dx.doi.org/10.1155/2013/834684 |
| spellingShingle | Jennifer H. Gunter Phoebe L. Sarkar Amy A. Lubik Colleen C. Nelson New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication International Journal of Cell Biology |
| title | New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication |
| title_full | New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication |
| title_fullStr | New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication |
| title_full_unstemmed | New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication |
| title_short | New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication |
| title_sort | new players for advanced prostate cancer and the rationalisation of insulin sensitising medication |
| url | http://dx.doi.org/10.1155/2013/834684 |
| work_keys_str_mv | AT jenniferhgunter newplayersforadvancedprostatecancerandtherationalisationofinsulinsensitisingmedication AT phoebelsarkar newplayersforadvancedprostatecancerandtherationalisationofinsulinsensitisingmedication AT amyalubik newplayersforadvancedprostatecancerandtherationalisationofinsulinsensitisingmedication AT colleencnelson newplayersforadvancedprostatecancerandtherationalisationofinsulinsensitisingmedication |